<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231010060921&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231010060921&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 10 Oct 2023 10:09:22 +0000</lastbuilddate>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Cardiac Troponins for Diagnosis and Prognostic Assessment of Immune Checkpoint Inhibitor Myocarditis and Myositis: The Emerging Importance of Peripheral Vision</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1135-1137. doi: 10.1161/CIRCULATIONAHA.123.065988. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37812655</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065988>10.1161/CIRCULATIONAHA.123.065988</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812655</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Christopher deFilippi</dc:creator>
<dc:creator>Ana Barac</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Troponins for Diagnosis and Prognostic Assessment of Immune Checkpoint Inhibitor Myocarditis and Myositis: The Emerging Importance of Peripheral Vision</dc:title>
<dc:identifier>pmid:37812655</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065988</dc:identifier>
</item>
<item>
<title>Letter by Krisai et al Regarding Article, "Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1182. doi: 10.1161/CIRCULATIONAHA.123.065076. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37812654</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065076>10.1161/CIRCULATIONAHA.123.065076</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812654</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Philipp Krisai</dc:creator>
<dc:creator>Michael Kühne</dc:creator>
<dc:creator>Christian Sticherling</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Krisai et al Regarding Article, "Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial"</dc:title>
<dc:identifier>pmid:37812654</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065076</dc:identifier>
</item>
<item>
<title>Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37812653/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 10;148(15):1179-1181. doi: 10.1161/CIRCULATIONAHA.123.065560. Epub 2023 Oct 9.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37812653/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37812653</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065560>10.1161/CIRCULATIONAHA.123.065560</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37812653</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Adelina Yafasova</dc:creator>
<dc:creator>Seiko N Doi</dc:creator>
<dc:creator>Jens C Nielsen</dc:creator>
<dc:creator>Jens Haarbo</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Axel Brandes</dc:creator>
<dc:creator>Anna M Thøgersen</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Jesper H Svendsen</dc:creator>
<dc:creator>Dan E Høfsten</dc:creator>
<dc:creator>Lars Videbæk</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Steen Pehrson</dc:creator>
<dc:creator>Jens Jakob Thune</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial</dc:title>
<dc:identifier>pmid:37812653</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065560</dc:identifier>
</item>
<item>
<title>Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system and has profound impacts on morbidity and mortality. There are multisystem consequences of poor cardiovascular-kidney-metabolic health, with the most significant clinical impact being the high associated incidence of cardiovascular disease events and cardiovascular mortality. There is a high prevalence of poor cardiovascular-kidney-metabolic health in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 9. doi: 10.1161/CIR.0000000000001184. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular-kidney-metabolic health reflects the interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system and has profound impacts on morbidity and mortality. There are multisystem consequences of poor cardiovascular-kidney-metabolic health, with the most significant clinical impact being the high associated incidence of cardiovascular disease events and cardiovascular mortality. There is a high prevalence of poor cardiovascular-kidney-metabolic health in the population, with a disproportionate burden seen among those with adverse social determinants of health. However, there is also a growing number of therapeutic options that favorably affect metabolic risk factors, kidney function, or both that also have cardioprotective effects. To improve cardiovascular-kidney-metabolic health and related outcomes in the population, there is a critical need for (1) more clarity on the definition of cardiovascular-kidney-metabolic syndrome; (2) an approach to cardiovascular-kidney-metabolic staging that promotes prevention across the life course; (3) prediction algorithms that include the exposures and outcomes most relevant to cardiovascular-kidney-metabolic health; and (4) strategies for the prevention and management of cardiovascular disease in relation to cardiovascular-kidney-metabolic health that reflect harmonization across major subspecialty guidelines and emerging scientific evidence. It is also critical to incorporate considerations of social determinants of health into care models for cardiovascular-kidney-metabolic syndrome and to reduce care fragmentation by facilitating approaches for patient-centered interdisciplinary care. This presidential advisory provides guidance on the definition, staging, prediction paradigms, and holistic approaches to care for patients with cardiovascular-kidney-metabolic syndrome and details a multicomponent vision for effectively and equitably enhancing cardiovascular-kidney-metabolic health in the population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37807924</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001184>10.1161/CIR.0000000000001184</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37807924</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Janani Rangaswami</dc:creator>
<dc:creator>Sheryl L Chow</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Katherine R Tuttle</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Jean-Pierre Despres</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Joshua J Joseph</dc:creator>
<dc:creator>Walter N Kernan</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn L Lekavich</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Kevin B Lo</dc:creator>
<dc:creator>Bige Ozkan</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>Sonali S Patel</dc:creator>
<dc:creator>Michael J Pencina</dc:creator>
<dc:creator>Tiffany M Powell-Wiley</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Jackson T Wright</dc:creator>
<dc:creator>Radhika Rajgopal Singh</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:37807924</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001184</dc:identifier>
</item>
<item>
<title>A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 9. doi: 10.1161/CIR.0000000000001186. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A growing appreciation of the pathophysiological interrelatedness of metabolic risk factors such as obesity and diabetes, chronic kidney disease, and cardiovascular disease has led to the conceptualization of cardiovascular-kidney-metabolic syndrome. The confluence of metabolic risk factors and chronic kidney disease within cardiovascular-kidney-metabolic syndrome is strongly linked to risk for adverse cardiovascular and kidney outcomes. In addition, there are unique management considerations for individuals with established cardiovascular disease and coexisting metabolic risk factors, chronic kidney disease, or both. An extensive body of literature supports our scientific understanding of, and approach to, prevention and management for individuals with cardiovascular-kidney-metabolic syndrome. However, there are critical gaps in knowledge related to cardiovascular-kidney-metabolic syndrome in terms of mechanisms of disease development, heterogeneity within clinical phenotypes, interplay between social determinants of health and biological risk factors, and accurate assessments of disease incidence in the context of competing risks. There are also key limitations in the data supporting the clinical care for cardiovascular-kidney-metabolic syndrome, particularly in terms of early-life prevention, screening for risk factors, interdisciplinary care models, optimal strategies for supporting lifestyle modification and weight loss, targeting of emerging cardioprotective and kidney-protective therapies, management of patients with both cardiovascular disease and chronic kidney disease, and the impact of systematically assessing and addressing social determinants of health. This scientific statement uses a crosswalk of major guidelines, in addition to a review of the scientific literature, to summarize the evidence and fundamental gaps related to the science, screening, prevention, and management of cardiovascular-kidney-metabolic syndrome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37807920</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001186>10.1161/CIR.0000000000001186</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37807920</guid>
<pubDate>Mon, 09 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Ian J Neeland</dc:creator>
<dc:creator>Katherine R Tuttle</dc:creator>
<dc:creator>Sheryl L Chow</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Carissa M Baker-Smith</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Jean-Pierre Després</dc:creator>
<dc:creator>Jennifer E Ho</dc:creator>
<dc:creator>Joshua J Joseph</dc:creator>
<dc:creator>Walter N Kernan</dc:creator>
<dc:creator>Amit Khera</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn L Lekavich</dc:creator>
<dc:creator>Eldrin F Lewis</dc:creator>
<dc:creator>Kevin B Lo</dc:creator>
<dc:creator>Bige Ozkan</dc:creator>
<dc:creator>Latha P Palaniappan</dc:creator>
<dc:creator>Sonali S Patel</dc:creator>
<dc:creator>Michael J Pencina</dc:creator>
<dc:creator>Tiffany M Powell-Wiley</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Jackson T Wright</dc:creator>
<dc:creator>Radhika Rajgopal Singh</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Janani Rangaswami</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-10-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:37807920</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001186</dc:identifier>
</item>
<item>
<title>Antagonistic RALF peptides control an intergeneric hybridization barrier on Brassicaceae stigmas</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Pollen-pistil interactions establish interspecific/intergeneric pre-zygotic hybridization barriers in plants. The rejection of undesired pollen at the stigma is crucial to avoid outcrossing but can be overcome with the support of mentor pollen. The mechanisms underlying this hybridization barrier are largely unknown. Here, in Arabidopsis, we demonstrate that receptor-like kinases FERONIA/CURVY1/ANJEA/HERCULES RECEPTOR KINASE 1 and cell wall proteins LRX3/4/5 interact on papilla cell surfaces...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 7:S0092-8674(23)00981-9. doi: 10.1016/j.cell.2023.09.003. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pollen-pistil interactions establish interspecific/intergeneric pre-zygotic hybridization barriers in plants. The rejection of undesired pollen at the stigma is crucial to avoid outcrossing but can be overcome with the support of mentor pollen. The mechanisms underlying this hybridization barrier are largely unknown. Here, in Arabidopsis, we demonstrate that receptor-like kinases FERONIA/CURVY1/ANJEA/HERCULES RECEPTOR KINASE 1 and cell wall proteins LRX3/4/5 interact on papilla cell surfaces with autocrine stigmatic RALF1/22/23/33 peptide ligands (sRALFs) to establish a lock that blocks the penetration of undesired pollen tubes. Compatible pollen-derived RALF10/11/12/13/25/26/30 peptides (pRALFs) act as a key, outcompeting sRALFs and enabling pollen tube penetration. By treating Arabidopsis stigmas with synthetic pRALFs, we unlock the barrier, facilitating pollen tube penetration from distantly related Brassicaceae species and resulting in interspecific/intergeneric hybrid embryo formation. Therefore, we uncover a "lock-and-key" system governing the hybridization breadth of interspecific/intergeneric crosses in Brassicaceae. Manipulating this system holds promise for facilitating broad hybridization in crops.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37806310</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.003>10.1016/j.cell.2023.09.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37806310</guid>
<pubDate>Sun, 08 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Zijun Lan</dc:creator>
<dc:creator>Zihan Song</dc:creator>
<dc:creator>Zhijuan Wang</dc:creator>
<dc:creator>Ling Li</dc:creator>
<dc:creator>Yiqun Liu</dc:creator>
<dc:creator>Shuaihua Zhi</dc:creator>
<dc:creator>Ruihan Wang</dc:creator>
<dc:creator>Jizong Wang</dc:creator>
<dc:creator>Qiyun Li</dc:creator>
<dc:creator>Andrea Bleckmann</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:creator>Thomas Dresselhaus</dc:creator>
<dc:creator>Juan Dong</dc:creator>
<dc:creator>Hongya Gu</dc:creator>
<dc:creator>Sheng Zhong</dc:creator>
<dc:creator>Li-Jia Qu</dc:creator>
<dc:date>2023-10-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Antagonistic RALF peptides control an intergeneric hybridization barrier on Brassicaceae stigmas</dc:title>
<dc:identifier>pmid:37806310</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.003</dc:identifier>
</item>
<item>
<title>Generative replay underlies compositional inference in the hippocampal-prefrontal circuit</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Human reasoning depends on reusing pieces of information by putting them together in new ways. However, very little is known about how compositional computation is implemented in the brain. Here, we ask participants to solve a series of problems that each require constructing a whole from a set of elements. With fMRI, we find that representations of novel constructed objects in the frontal cortex and hippocampus are relational and compositional. With MEG, we find that replay assembles elements...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 30:S0092-8674(23)01025-5. doi: 10.1016/j.cell.2023.09.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Human reasoning depends on reusing pieces of information by putting them together in new ways. However, very little is known about how compositional computation is implemented in the brain. Here, we ask participants to solve a series of problems that each require constructing a whole from a set of elements. With fMRI, we find that representations of novel constructed objects in the frontal cortex and hippocampus are relational and compositional. With MEG, we find that replay assembles elements into compounds, with each replay sequence constituting a hypothesis about a possible configuration of elements. The content of sequences evolves as participants solve each puzzle, progressing from predictable to uncertain elements and gradually converging on the correct configuration. Together, these results suggest a computational bridge between apparently distinct functions of hippocampal-prefrontal circuitry and a role for generative replay in compositional inference and hypothesis testing.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804832</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.004>10.1016/j.cell.2023.09.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804832</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Philipp Schwartenbeck</dc:creator>
<dc:creator>Alon Baram</dc:creator>
<dc:creator>Yunzhe Liu</dc:creator>
<dc:creator>Shirley Mark</dc:creator>
<dc:creator>Timothy Muller</dc:creator>
<dc:creator>Raymond Dolan</dc:creator>
<dc:creator>Matthew Botvinick</dc:creator>
<dc:creator>Zeb Kurth-Nelson</dc:creator>
<dc:creator>Timothy Behrens</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Generative replay underlies compositional inference in the hippocampal-prefrontal circuit</dc:title>
<dc:identifier>pmid:37804832</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.004</dc:identifier>
</item>
<item>
<title>Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>MXRA8 is a receptor for chikungunya (CHIKV) and other arthritogenic alphaviruses with mammalian hosts. However, mammalian MXRA8 does not bind to alphaviruses that infect humans and have avian reservoirs. Here, we show that avian, but not mammalian, MXRA8 can act as a receptor for Sindbis, western equine encephalitis (WEEV), and related alphaviruses with avian reservoirs. Structural analysis of duck MXRA8 complexed with WEEV reveals an inverted binding mode compared with mammalian MXRA8 bound to...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 2:S0092-8674(23)01029-2. doi: 10.1016/j.cell.2023.09.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MXRA8 is a receptor for chikungunya (CHIKV) and other arthritogenic alphaviruses with mammalian hosts. However, mammalian MXRA8 does not bind to alphaviruses that infect humans and have avian reservoirs. Here, we show that avian, but not mammalian, MXRA8 can act as a receptor for Sindbis, western equine encephalitis (WEEV), and related alphaviruses with avian reservoirs. Structural analysis of duck MXRA8 complexed with WEEV reveals an inverted binding mode compared with mammalian MXRA8 bound to CHIKV. Whereas both domains of mammalian MXRA8 bind CHIKV E1 and E2, only domain 1 of avian MXRA8 engages WEEV E1, and no appreciable contacts are made with WEEV E2. Using these results, we generated a chimeric avian-mammalian MXRA8 decoy-receptor that neutralizes infection of multiple alphaviruses from distinct antigenic groups in vitro and in vivo. Thus, different alphaviruses can bind MXRA8 encoded by different vertebrate classes with distinct engagement modes, which enables development of broad-spectrum inhibitors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804831</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.007>10.1016/j.cell.2023.09.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804831</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Ofer Zimmerman</dc:creator>
<dc:creator>Maxwell I Zimmerman</dc:creator>
<dc:creator>Saravanan Raju</dc:creator>
<dc:creator>Christopher A Nelson</dc:creator>
<dc:creator>John M Errico</dc:creator>
<dc:creator>Emily A Madden</dc:creator>
<dc:creator>Autumn C Holmes</dc:creator>
<dc:creator>Ahmed O Hassan</dc:creator>
<dc:creator>Laura A VanBlargan</dc:creator>
<dc:creator>Arthur S Kim</dc:creator>
<dc:creator>Lucas J Adams</dc:creator>
<dc:creator>Katherine Basore</dc:creator>
<dc:creator>Bradley M Whitener</dc:creator>
<dc:creator>Sathvik Palakurty</dc:creator>
<dc:creator>Hannah G Davis-Adams</dc:creator>
<dc:creator>Chengqun Sun</dc:creator>
<dc:creator>Theron Gilliland</dc:creator>
<dc:creator>James T Earnest</dc:creator>
<dc:creator>Hongming Ma</dc:creator>
<dc:creator>Gregory D Ebel</dc:creator>
<dc:creator>Christian Zmasek</dc:creator>
<dc:creator>Richard H Scheuermann</dc:creator>
<dc:creator>William B Klimstra</dc:creator>
<dc:creator>Daved H Fremont</dc:creator>
<dc:creator>Michael S Diamond</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8</dc:title>
<dc:identifier>pmid:37804831</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.007</dc:identifier>
</item>
<item>
<title>Arginine reprograms metabolism in liver cancer via RBM39</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 26:S0092-8674(23)01032-2. doi: 10.1016/j.cell.2023.09.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of arginine promote tumor formation via further metabolic reprogramming, including changes in glucose, amino acid, nucleotide, and fatty acid metabolism. Mechanistically, arginine binds RNA-binding motif protein 39 (RBM39) to control expression of metabolic genes. RBM39-mediated upregulation of asparagine synthesis leads to enhanced arginine uptake, creating a positive feedback loop to sustain high arginine levels and oncogenic metabolism. Thus, arginine is a second messenger-like molecule that reprograms metabolism to promote tumor growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804830</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.011>10.1016/j.cell.2023.09.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804830</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dirk Mossmann</dc:creator>
<dc:creator>Christoph Müller</dc:creator>
<dc:creator>Sujin Park</dc:creator>
<dc:creator>Brendan Ryback</dc:creator>
<dc:creator>Marco Colombi</dc:creator>
<dc:creator>Nathalie Ritter</dc:creator>
<dc:creator>Diana Weißenberger</dc:creator>
<dc:creator>Eva Dazert</dc:creator>
<dc:creator>Mairene Coto-Llerena</dc:creator>
<dc:creator>Sandro Nuciforo</dc:creator>
<dc:creator>Lauriane Blukacz</dc:creator>
<dc:creator>Caner Ercan</dc:creator>
<dc:creator>Veronica Jimenez</dc:creator>
<dc:creator>Salvatore Piscuoglio</dc:creator>
<dc:creator>Fatima Bosch</dc:creator>
<dc:creator>Luigi M Terracciano</dc:creator>
<dc:creator>Uwe Sauer</dc:creator>
<dc:creator>Markus H Heim</dc:creator>
<dc:creator>Michael N Hall</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Arginine reprograms metabolism in liver cancer via RBM39</dc:title>
<dc:identifier>pmid:37804830</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.011</dc:identifier>
</item>
<item>
<title>Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 28:S0735-1097(23)06403-3. doi: 10.1016/j.jacc.2023.08.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804294</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.008>10.1016/j.jacc.2023.08.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804294</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Matthew K Lawlor</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Vinay Badhwar</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Ernest Spitzer</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Brian R Lindman</dc:creator>
<dc:creator>Yan Topilsky</dc:creator>
<dc:creator>Suzanne J Baron</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Omar K Khalique</dc:creator>
<dc:creator>Gilbert H L Tang</dc:creator>
<dc:creator>Maurizio Taramasso</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Luigi Badano</dc:creator>
<dc:creator>Jonathon Leipsic</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Sreekanth Vemulapalli</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Maria C Alu</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Gorav Ailawadi</dc:creator>
<dc:creator>Michael Mack</dc:creator>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:creator>TVARC Steering Committee</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints</dc:title>
<dc:identifier>pmid:37804294</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.008</dc:identifier>
</item>
<item>
<title>Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target the hyper-contractile phenotype, which plays a critical role in the pathophysiology of the disease. In Phase 2 and 3 clinical trials, mavacamten was well tolerated, reduced left ventricular outflow...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 7:ehad637. doi: 10.1093/eurheartj/ehad637. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target the hyper-contractile phenotype, which plays a critical role in the pathophysiology of the disease. In Phase 2 and 3 clinical trials, mavacamten was well tolerated, reduced left ventricular outflow tract gradients, improved exercise capacity and symptoms, and was associated with improvements in other clinically relevant parameters, such as patient-reported outcomes and circulating biomarkers. In addition, treatment with mavacamten was associated with evidence of favourable cardiac remodelling in multi-modality imaging studies. Mavacamten substantially reduced guideline eligibility for septal reduction therapy candidates with oHCM and drug-refractory symptoms. In this article, the available efficacy and safety data from completed and ongoing clinical studies of mavacamten in patients with symptomatic oHCM are reviewed. Longer term extension studies may help address questions related to the positioning of mavacamten in current oHCM management algorithms, interactions with background therapy, as well as the potential for disease modification beyond symptomatic relief of left ventricular outflow tract obstruction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804245</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad637>10.1093/eurheartj/ehad637</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804245</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Perry M Elliott</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:37804245</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad637</dc:identifier>
</item>
<item>
<title>A 20-year population study of peripartum cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: PPCM affected 1 in 4950 women around the time of pregnancy. The condition is associated with considerable morbidity and mortality for the mother and child. There should be a low threshold for investigating at-risk women. Long term follow-up, despite apparent recovery, should be considered.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 7:ehad626. doi: 10.1093/eurheartj/ehad626. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The epidemiology of peripartum cardiomyopathy (PPCM) in Europe is poorly understood and data on long-term outcomes are lacking. A retrospective, observational, population-level study of validated cases of PPCM in Scotland from 1998 to 2017 was conducted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Women hospitalized with presumed de novo left ventricular systolic dysfunction around the time of pregnancy and no clear alternative cause were included. Each case was matched to 10 controls. Incidence and risk factors were identified. Morbidity and mortality were examined in mothers and children.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The incidence of PPCM was 1 in 4950 deliveries. Among 225 women with PPCM, obesity, gestational hypertensive disorders, and multi-gestation were found to be associated with having the condition. Over a median of 8.3 years (9.7 years for echocardiographic outcomes), 8% of women with PPCM died and 75% were rehospitalized for any cause at least once. Mortality and rehospitalization rates in women with PPCM were ∼12- and ∼3-times that of controls, respectively. The composite of all-cause death, mechanical circulatory support, or cardiac transplantation occurred in 14%. LV recovery occurred in 76% and, of those who recovered, 13% went on to have a decline in LV systolic function despite initial recovery. The mortality rate for children born to women with PPCM was ∼5-times that of children born to controls and they had an ∼3-times greater incidence of cardiovascular disease over a median of 8.8 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PPCM affected 1 in 4950 women around the time of pregnancy. The condition is associated with considerable morbidity and mortality for the mother and child. There should be a low threshold for investigating at-risk women. Long term follow-up, despite apparent recovery, should be considered.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37804234</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad626>10.1093/eurheartj/ehad626</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37804234</guid>
<pubDate>Sat, 07 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Alice M Jackson</dc:creator>
<dc:creator>Mark Macartney</dc:creator>
<dc:creator>Katriona Brooksbank</dc:creator>
<dc:creator>Carolyn Brown</dc:creator>
<dc:creator>Dana Dawson</dc:creator>
<dc:creator>Mark Francis</dc:creator>
<dc:creator>Alan Japp</dc:creator>
<dc:creator>Vera Lennie</dc:creator>
<dc:creator>Stephen J Leslie</dc:creator>
<dc:creator>Thomas Martin</dc:creator>
<dc:creator>Paul Neary</dc:creator>
<dc:creator>Sowmya Venkatasubramanian</dc:creator>
<dc:creator>Debra Vickers</dc:creator>
<dc:creator>Robin A Weir</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:date>2023-10-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A 20-year population study of peripartum cardiomyopathy</dc:title>
<dc:identifier>pmid:37804234</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad626</dc:identifier>
</item>
<item>
<title>Limited-resource, limited-guideline? Towards the delivery of appropriate and contextual cardiovascular care across settings</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 6:ehad253. doi: 10.1093/eurheartj/ehad253. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37801634</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad253>10.1093/eurheartj/ehad253</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37801634</guid>
<pubDate>Fri, 06 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dominique Vervoort</dc:creator>
<dc:date>2023-10-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Limited-resource, limited-guideline? Towards the delivery of appropriate and contextual cardiovascular care across settings</dc:title>
<dc:identifier>pmid:37801634</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad253</dc:identifier>
</item>
<item>
<title>Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of &lt;em>;CDCP1&lt;/em>; and Cardiac Fibrosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: CDCP1 may play an important role in myocardial recovery in recent-onset DCM and mediates its effect primarily by attenuating cardiac fibrosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 6. doi: 10.1161/CIRCRESAHA.123.323200. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dilated cardiomyopathy (DCM) is a major cause of heart failure and carries a high mortality rate. Myocardial recovery in DCM-related heart failure patients is highly variable, with some patients having little or no response to standard drug therapy. A genome-wide association study may agnostically identify biomarkers and provide novel insight into the biology of myocardial recovery in DCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A genome-wide association study for change in left ventricular ejection fraction was performed in 686 White subjects with recent-onset DCM who received standard pharmacotherapy. Genome-wide association study signals were subsequently functionally validated and studied in relevant cellular models to understand molecular mechanisms that may have contributed to the change in left ventricular ejection fraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The genome-wide association study identified a highly suggestive locus that mapped to the 5'-flanking region of the <i>CDCP1</i> (CUB domain containing protein 1) gene (rs6773435; <i>P</i>=7.12×10<sup>-</sup><sup>7</sup>). The variant allele was associated with improved cardiac function and decreased <i>CDCP1</i> transcription. CDCP1 expression was significantly upregulated in human cardiac fibroblasts (HCFs) in response to the PDGF (platelet-derived growth factor) signaling, and knockdown of CDCP1 significantly repressed HCF proliferation and decreased AKT phosphorylation. Transcriptomic profiling after CDCP1 knockdown in HCFs supported the conclusion that CDCP1 regulates HCF proliferation and mitosis. In addition, CDCP1 knockdown in HCFs resulted in significantly decreased expression of soluble ST2, a prognostic biomarker for heart failure and inductor of cardiac fibrosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: <i>CDCP1</i> may play an important role in myocardial recovery in recent-onset DCM and mediates its effect primarily by attenuating cardiac fibrosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37800334</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323200>10.1161/CIRCRESAHA.123.323200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37800334</guid>
<pubDate>Fri, 06 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Duan Liu</dc:creator>
<dc:creator>Min Wang</dc:creator>
<dc:creator>Vishakantha Murthy</dc:creator>
<dc:creator>Dennis M McNamara</dc:creator>
<dc:creator>Thanh Thanh L Nguyen</dc:creator>
<dc:creator>Trudy J Philips</dc:creator>
<dc:creator>Hridyanshu Vyas</dc:creator>
<dc:creator>Huanyao Gao</dc:creator>
<dc:creator>Jyotan Sahni</dc:creator>
<dc:creator>Randall C Starling</dc:creator>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Michelle K Skime</dc:creator>
<dc:creator>Anthony Batzler</dc:creator>
<dc:creator>Gregory D Jenkins</dc:creator>
<dc:creator>Simona Barlera</dc:creator>
<dc:creator>Silvana Pileggi</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Florence Pinet</dc:creator>
<dc:creator>Jan Krejčí</dc:creator>
<dc:creator>Anna Chaloupka</dc:creator>
<dc:creator>Jordan D Miller</dc:creator>
<dc:creator>Pascal de Groote</dc:creator>
<dc:creator>Daniel J Tschumperlin</dc:creator>
<dc:creator>Richard M Weinshilboum</dc:creator>
<dc:creator>Naveen L Pereira</dc:creator>
<dc:creator>IMAC-2 Investigators</dc:creator>
<dc:date>2023-10-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of &lt;em>;CDCP1&lt;/em>; and Cardiac Fibrosis</dc:title>
<dc:identifier>pmid:37800334</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323200</dc:identifier>
</item>
<item>
<title>Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Aging-associated impairment of vascular repair is partly determined by the vasoprotective enzyme CSE.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 6. doi: 10.1161/CIRCRESAHA.123.323084. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Advanced age is unequivocally linked to the development of cardiovascular disease; however, the mechanisms resulting in reduced endothelial cell regeneration remain poorly understood. Here, we investigated novel mechanisms involved in endothelial cell senescence that impact endothelial cell transcription and vascular repair after injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Native endothelial cells were isolated from young (20±3.4 years) and aged (80±2.3 years) individuals and subjected to molecular analyses to assess global transcriptional and metabolic changes. in vitro studies were conducted using primary human and murine endothelial cells. A murine aortic reendothelialization model was used to examine endothelial cell regenerative capacity in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: RNA sequencing of native endothelial cells revealed that aging resulted in p53-mediated reprogramming to express senescence-associated genes and suppress glycolysis. Reduced glucose uptake and ATP contributed to attenuated assembly of the telomerase complex, which was required for endothelial cell proliferation. Enhanced p53 activity in aging was linked to its acetylation on K120 due to enhanced activity of the acetyltransferase MOZ (monocytic leukemic zinc finger). Mechanistically, p53 acetylation and translocation were, at least partially, attributed to the loss of the vasoprotective enzyme, CSE (cystathionine γ-lyase). CSE physically anchored p53 in the cytosol to prevent its nuclear translocation and in its absence inhibited Akt-mediated MOZ phosphorylation, which in turn increased MOZ activity and subsequently p53 acetylation. In mice, the endothelial cell-specific deletion of CSE activated p53, induced premature endothelial senescence, and arrested vascular repair after injury. In contrast, the adeno-associated virus 9-mediated reexpression of an active CSE mutant retained p53 in the cytosol, maintained endothelial glucose metabolism and proliferation, and prevented endothelial cell senescence. Adenoviral overexpression of CSE in native endothelial cells from aged individuals maintained low p53 activity and reactivated telomerase to revert endothelial cell senescence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Aging-associated impairment of vascular repair is partly determined by the vasoprotective enzyme CSE.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37800327</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323084>10.1161/CIRCRESAHA.123.323084</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37800327</guid>
<pubDate>Fri, 06 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jiong Hu</dc:creator>
<dc:creator>Matthias S Leisegang</dc:creator>
<dc:creator>Mario Looso</dc:creator>
<dc:creator>Maria-Kyriaki Drekolia</dc:creator>
<dc:creator>Janina Wittig</dc:creator>
<dc:creator>Janina Mettner</dc:creator>
<dc:creator>Christina Karantanou</dc:creator>
<dc:creator>Anastasia Kyselova</dc:creator>
<dc:creator>Gabrjela Dumbovic</dc:creator>
<dc:creator>Xiaoming Li</dc:creator>
<dc:creator>Yuanyuan Li</dc:creator>
<dc:creator>Stefan Guenther</dc:creator>
<dc:creator>David John</dc:creator>
<dc:creator>Mauro Siragusa</dc:creator>
<dc:creator>Sven Zukunft</dc:creator>
<dc:creator>James Oo</dc:creator>
<dc:creator>Ilka Wittig</dc:creator>
<dc:creator>Susanne Hille</dc:creator>
<dc:creator>Andreas Weigert</dc:creator>
<dc:creator>Stefan Knapp</dc:creator>
<dc:creator>Ralf P Brandes</dc:creator>
<dc:creator>Oliver J Müller</dc:creator>
<dc:creator>Andreas Papapetropoulos</dc:creator>
<dc:creator>Fragiska Sigala</dc:creator>
<dc:creator>Gergana Dobreva</dc:creator>
<dc:creator>Baktybek Kojonazarov</dc:creator>
<dc:creator>Ingrid Fleming</dc:creator>
<dc:creator>Sofia-Iris Bibli</dc:creator>
<dc:date>2023-10-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence</dc:title>
<dc:identifier>pmid:37800327</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323084</dc:identifier>
</item>
<item>
<title>Brain endothelium: a nexus for cerebral small vessel disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 29:ehad526. doi: 10.1093/eurheartj/ehad526. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37798089</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad526>10.1093/eurheartj/ehad526</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37798089</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Frank M Faraci</dc:creator>
<dc:creator>BRENDA Network</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Brain endothelium: a nexus for cerebral small vessel disease</dc:title>
<dc:identifier>pmid:37798089</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad526</dc:identifier>
</item>
<item>
<title>The European Society of Cardiology working group on cardiovascular pharmacotherapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 4:ehad651. doi: 10.1093/eurheartj/ehad651. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37796825</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad651>10.1093/eurheartj/ehad651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37796825</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Juan Carlos Kaski</dc:creator>
<dc:creator>Alexander Niessner</dc:creator>
<dc:creator>Dobromir Dobrev</dc:creator>
<dc:creator>Bianca Rocca</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European Society of Cardiology working group on cardiovascular pharmacotherapy</dc:title>
<dc:identifier>pmid:37796825</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad651</dc:identifier>
</item>
<item>
<title>Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 5:ehad581. doi: 10.1093/eurheartj/ehad581. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardioverter defibrillator (ICD) implantation in primary prevention for sudden cardiac death (SCD) is crucial. The aim of this study was to externally validate the 2022 European Society of Cardiology (ESC) model and other guideline-based ICD class of recommendation (ICD-COR) models and explore the utility of late gadolinium enhancement (LGE) in further risk stratification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Seven hundred and seventy-four consecutive patients who underwent cardiac magnetic resonance imaging were retrospectively enrolled.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-six (5.9%) patients reached the SCD-related endpoint during 7.4 ± 2.5 years of follow-up. Patients suffering from SCD had higher ESC Risk-SCD score (4.3 ± 2.4% vs. 2.8 ± 2.1%, P &lt; .001) and LGE extent (13.7 ± 9.4% vs. 4.9 ± 6.6%, P &lt; .001). Compared with the 2014 ESC model, the 2022 ESC model showed increased area under the curve (.76 vs. .63), sensitivity (76.1% vs. 43.5%), positive predictive value (16.8% vs. 13.6%), and negative predictive value (98.1% vs. 95.9%). The C-statistics for SCD prediction of 2011 American College of Cardiology (ACC)/American Heart Association (AHA), 2014 ESC, 2020 AHA/ACC, and 2022 ESC models were .68, .64, .76 and .78, respectively. Furthermore, in patients without extensive LGE, LGE ≥5% was responsible for seven-fold SCD risk after multivariable adjustment. Whether in ICD-COR II or ICD-COR III, patients with LGE ≥5% and &lt;15% showed significantly worse prognosis than those with LGE &lt;5% (all P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37795986</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad581>10.1093/eurheartj/ehad581</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795986</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Jiaxin Wang</dc:creator>
<dc:creator>Shujuan Yang</dc:creator>
<dc:creator>Xuan Ma</dc:creator>
<dc:creator>Kankan Zhao</dc:creator>
<dc:creator>Kai Yang</dc:creator>
<dc:creator>Shiqin Yu</dc:creator>
<dc:creator>Gang Yin</dc:creator>
<dc:creator>Zhixiang Dong</dc:creator>
<dc:creator>Yanyan Song</dc:creator>
<dc:creator>Chen Cui</dc:creator>
<dc:creator>Jinghui Li</dc:creator>
<dc:creator>Chuangshi Wang</dc:creator>
<dc:creator>Jun Hao</dc:creator>
<dc:creator>Minjie Lu</dc:creator>
<dc:creator>Xiuyu Chen</dc:creator>
<dc:creator>Shihua Zhao</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</dc:title>
<dc:identifier>pmid:37795986</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad581</dc:identifier>
</item>
<item>
<title>Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIR.0000000000001180. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the risk of infective endocarditis have been limited by inadequate sample size. They have typically focused on a few potential at-risk surgical and nonsurgical invasive procedures. However, recent investigations from Sweden and England that used nationwide databases and demonstrated an association between nondental invasive procedures, and the subsequent development of infective endocarditis (in particular, in high-risk patients with infective endocarditis) prompted the development of the current science advisory.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37795631</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001180>10.1161/CIR.0000000000001180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795631</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Larry M Baddour</dc:creator>
<dc:creator>Imre Janszky</dc:creator>
<dc:creator>Martin H Thornhill</dc:creator>
<dc:creator>Zerelda Esquer Garrigos</dc:creator>
<dc:creator>Daniel C DeSimone</dc:creator>
<dc:creator>Karen Welty-Wolf</dc:creator>
<dc:creator>Annette L Baker</dc:creator>
<dc:creator>Pei-Ni Jone</dc:creator>
<dc:creator>Bernard Prendergast</dc:creator>
<dc:creator>Mark J Dayer</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts) and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:37795631</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001180</dc:identifier>
</item>
<item>
<title>Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo(2), complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.065192. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Annual medical history was collected through record review and telephone interviews. Cardiac magnetic resonance imaging (CMR), echocardiogram, and cycle ergometry cardiopulmonary exercise tests were performed at 10 through 14 years of age among participants with Fontan physiology. Differences in transplant-free survival and complication rates (eg, arrhythmias or protein-losing enteropathy) were identified through 12 years of age. The primary study outcome was right ventricular ejection fraction (RVEF) by CMR, and primary analyses were according to shunt type received. Multivariable linear and Cox regression models were created for RVEF by CMR and post-Fontan transplant-free survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 549 participants enrolled in SVR, 237 of 313 (76%; 60.7% male) transplant-free survivors (mBTTS, 105 of 147; RVPAS, 129 of 161; both, 3 of 5) participated in SVRIII. RVEF by CMR was similar in the shunt groups (RVPAS, 51±9.6 [n=90], and mBTTS, 52±7.4 [n=75]; <i>P</i>=0.43). The RVPAS and mBTTS groups did not differ in transplant-free survival by 12 years of age (163 of 277 [59%] versus 144 of 267 [54%], respectively; <i>P</i>=0.11), percentage predicted peak Vo<sub>2</sub> for age and sex (74±18% [n=91] versus 72±18% [n=84]; <i>P</i>=0.71), or percentage predicted work rate for size and sex (65±20% versus 64±19%; <i>P</i>=0.65). The RVPAS versus mBTTS group had a higher cumulative incidence of protein-losing enteropathy (5% versus 2%; <i>P</i>=0.04) and of catheter interventions (14 versus 10 per 100 patient-years; <i>P</i>=0.01), but had similar rates of other complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo<sub>2</sub>, complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT00115934.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37795623</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065192>10.1161/CIRCULATIONAHA.123.065192</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795623</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Caren S Goldberg</dc:creator>
<dc:creator>Felicia Trachtenberg</dc:creator>
<dc:creator>J William Gaynor</dc:creator>
<dc:creator>William T Mahle</dc:creator>
<dc:creator>Chitra Ravishankar</dc:creator>
<dc:creator>Steven M Schwartz</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Richard G Ohye</dc:creator>
<dc:creator>Russell Gongwer</dc:creator>
<dc:creator>Michael Taylor</dc:creator>
<dc:creator>Stephen Paridon</dc:creator>
<dc:creator>Peter C Frommelt</dc:creator>
<dc:creator>Katherine Afton</dc:creator>
<dc:creator>Andrew M Atz</dc:creator>
<dc:creator>Kristin M Burns</dc:creator>
<dc:creator>Jon A Detterich</dc:creator>
<dc:creator>Kevin D Hill</dc:creator>
<dc:creator>Antonio G Cabrera</dc:creator>
<dc:creator>Alan B Lewis</dc:creator>
<dc:creator>Christian Pizarro</dc:creator>
<dc:creator>Amee Shah</dc:creator>
<dc:creator>Binu Sharma</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>Pediatric Heart Network Investigators</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</dc:title>
<dc:identifier>pmid:37795623</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065192</dc:identifier>
</item>
<item>
<title>Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231010060921&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.064751. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. After coronary computed tomography angiography, patients with unobstructed coronary arteries, and who consented, underwent invasive endotyping. The diagnostic assessments included coronary angiography, fractional flow reserve (patient excluded if ≤0.80), and, for those without obstructive coronary artery disease, coronary flow reserve (abnormal &lt;2.0), index of microvascular resistance (abnormal ≥25), and intracoronary infusion of acetylcholine (0.182, 1.82, and 18.2 μg/mL; 2 mL/min for 2 minutes) to assess for microvascular and coronary spasm. Participants were randomly assigned to disclosure of the results of the coronary function tests to the invasive cardiologist (intervention group) or nondisclosure (control group, blinded). In the control group, a diagnosis of vasomotor angina was based on medical history, noninvasive tests, and coronary angiography. The primary outcome was the between-group difference in the reclassification rate of the initial diagnosis on the basis of coronary computed tomography angiography versus the final diagnosis after invasive endotyping. The Seattle Angina Questionnaire summary score and Treatment Satisfaction Questionnaire for Medication were secondary outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 322 eligible patients, 250 (77.6%) underwent invasive endotyping; 19 (7.6%) had obstructive coronary disease, 127 (55.0%) had microvascular angina, 27 (11.7%) had vasospastic angina, 17 (7.4%) had both, and 60 (26.0%) had no abnormality. A total of 231 patients (mean age, 55.7 years; 64.5% women) were randomly assigned and followed up (median duration, 19.9 [12.6-26.9] months). The clinician diagnosed vasomotor angina in 51 (44.3%) patients in the intervention group and in 55 (47.4%) patients in the control group. After randomization, patients in the intervention group were 4-fold (odds ratio, 4.05 [95% CI, 2.32-7.24]; <i>P</i>&lt;0.001) more likely to be diagnosed with a coronary vasomotor disorder; the frequency of this diagnosis increased to 76.5%. The frequency of normal coronary function (ie, no vasomotor disorder) was not different between the groups before randomization (51.3% versus 50.9%) but was reduced in the intervention group after randomization (23.5% versus 50.9%, <i>P</i>&lt;0.001). At 6 and 12 months, the Seattle Angina Questionnaire summary score in the intervention versus control groups was 59.2±24.2 (2.3±16.2 change from baseline) versus 60.4±23.9 (4.6±16.4 change) and 63.7±23.5 (4.7±14.7 change) versus 66.0±19.3 (7.9±17.1 change), respectively, and not different between groups (global <i>P</i>=0.36). Compared with the control group, global treatment satisfaction was higher in the intervention group at 12 months (69.9±22.8 versus 61.7±26.9, <i>P</i>=0.013).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03477890.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231010060921&v=2.17.9.post6+86293ac">37795617</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064751>10.1161/CIRCULATIONAHA.123.064751</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37795617</guid>
<pubDate>Thu, 05 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Novalia P Sidik</dc:creator>
<dc:creator>Bethany Stanley</dc:creator>
<dc:creator>Robert Sykes</dc:creator>
<dc:creator>Andrew J Morrow</dc:creator>
<dc:creator>Conor P Bradley</dc:creator>
<dc:creator>Michael McDermott</dc:creator>
<dc:creator>Thomas J Ford</dc:creator>
<dc:creator>Giles Roditi</dc:creator>
<dc:creator>Allister Hargreaves</dc:creator>
<dc:creator>David Stobo</dc:creator>
<dc:creator>Jacqueline Adams</dc:creator>
<dc:creator>John Byrne</dc:creator>
<dc:creator>Ahmed Mahrous</dc:creator>
<dc:creator>Robin Young</dc:creator>
<dc:creator>David Carrick</dc:creator>
<dc:creator>Ross McGeoch</dc:creator>
<dc:creator>David Corcoran</dc:creator>
<dc:creator>Ninian N Lang</dc:creator>
<dc:creator>Robert Heggie</dc:creator>
<dc:creator>Olivia Wu</dc:creator>
<dc:creator>Margaret B McEntegart</dc:creator>
<dc:creator>Alex McConnachie</dc:creator>
<dc:creator>Colin Berry</dc:creator>
<dc:date>2023-10-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:37795617</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064751</dc:identifier>
</item>





























</channel>
</rss>